Search results for: 'Artificial Intelligence Enabling the Global Geospatial Value-added Services Market'

The medical imaging and informatics industry is evolving, with vendors launching new products and solutions every other day. As the reimbursement environment transitions from fee-for-service to value-based payment, vendors business models and value propositions are changing. New evidence on the use of specific imaging techniques is influencing chan...

Frost & Sullivan research found the visible market success of artificial intelligence (AI)-driven interactive virtual assistants (IVAs), such as Alexa from Amazon and the Google Assistant, has been matched by specialized IVA deployments in various vertical markets such as financial services, education, and retail. Healthcare has presented opportun...

The value-based care (VBC) model aims to offer better outcomes and care quality to patients cost-effectively. Multiple stakeholders, including payers, healthcare providers, and medical technology (medtech) players, can share the revenue risk and incentive for providing better value. The United States is a pioneer in VBC adoption, followed by countr...

According to the Centers for Medicare and Medicaid Services (CMS), value-based care (VBC) programs reward healthcare providers with incentive payments for the quality of care they provide Medicare patients. These programs are part of its larger CMS quality strategy to reform healthcare delivery and payment. Value-based programs support 3 aims: b...

The global healthcare industry is in need of solutions that augment providers with insights to make meaningful clinical decisions within less turnaround times, which is critical to demonstrating value of care. Artificial Intelligence has proven its utility in performing data-mining activities on large sets of patient and population health data, add...

Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical r...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

23 Aug 2022  |  North America  |  Market Research

Global Bioanalytical Testing Services, 2021–2027

Acquisition of Disruptive Technologies will be the Key to Driving Growth

Infographics

×

Key Issues Addressed

As the pharma market recovers from the debilitating impact of COVID-19 on the drug discovery and development pipelines, there is an increasing requirement for outsourcing services in the form of contract research organizations (CROs) and contract development & manufacturing organizations (CDMOs), which is likely to drive the already strong drug dev...